Whose health outcomes should be considered for maternal-perinatal interventions delivered during pregnancy or childbirth?

Whose health outcomes should be considered for maternal-perinatal interventions delivered during pregnancy or childbirth?

If a child dies during childbirth, should the impact of the child's death on parental quality of life be considered? What about interventions that prevent miscarriages; should the health of the fetus be considered or only that of the mother? A paper by Lamsal et al. (2024) conducts a systematic review to examine which individual's health outcomes are being considered in cost-utility analysis (CUA) of maternal-perinatal interventions. They find:

Out of 174 maternal-perinatal CUAs identified, 62 considered the health outcomes of pregnant women, and children. Among the 54 quality-adjusted life year (QALY)-based CUAs, 12 included fetal health outcomes, the impact of fetal loss on mothers’ HRQoL, and the impact of neonatal demise on mothers’ HRQoL. Four studies considered fetal health outcomes and the effects of fetal loss on mothers’ HRQoL. One study included fetal health outcomes and the impact of neonatal demise on maternal HRQoL. Furthermore, six studies considered the impact of neonatal demise on maternal HRQoL, while four included fetal health outcomes. One study included the impact of fetal loss on maternal HRQoL. The remaining 26 only included the health outcomes of pregnant women and children. Among the eight disability-adjusted life year (DALY)-based CUAs, two measured fetal health outcomes. Out of 174 studies, only one study included family spillover effects. The most common measurement approach was to measure the health outcomes of pregnant women and children separately. Various approaches were used to assess fetal losses in terms of QALYs or DALYs and their impact on HRQoL of mothers. The most common integration approach was to sum the QALYs or DALYs for pregnant women and children. Most studies reported combined QALYs and incremental QALYs, or DALYs and incremental DALYs, at the family level for pregnant women and children.

You can review all the studies that the co-authors identified here.

Originally posted at Healthcare Economist.?

The views expressed herein are those of the author and not necessarily the views of?FTI Consulting, Inc., its management, its subsidiaries, its affiliates, or its other professionals.

要查看或添加评论,请登录

Jason Shafrin的更多文章

  • Calculating Social Vulnerability Index by ZIP Code

    Calculating Social Vulnerability Index by ZIP Code

    A paper by Ng, Zhang and Kowal (2025) use the American Community Survey (ACS) data from 2016–2022 were used to…

    2 条评论
  • Value-Based Pricing for Drugs With Uncertain Clinical Benefits

    Value-Based Pricing for Drugs With Uncertain Clinical Benefits

    This is the title of a recent paper by Jiao et al. (2025).

    1 条评论
  • About face for RFK Jr. on MMR vaccine?

    About face for RFK Jr. on MMR vaccine?

    Last month, I noted that the decrease in vaccination rates has likely resulted in increased rates of measles in Texas…

    1 条评论
  • The value of knowing is not always positive

    The value of knowing is not always positive

    An interesting article by Ciancio et al. (2025) which examines the impact of learning one has HIV when no treatment is…

    1 条评论
  • More evidence that there are diminishing marginal returns to quality of life gains

    More evidence that there are diminishing marginal returns to quality of life gains

    Quality-adjusted life years (QALYs) are commonly used to evaluate the impact of new medical technologies on patient…

  • Quotation of the Day

    Quotation of the Day

    There is nothing so useless as doing efficiently that which should not be done at all. Peter Drucker

    1 条评论
  • What is Project IDEATE?

    What is Project IDEATE?

    How best can you design an outcomes based agreement (OBA)? What are the key factors to consider? Project IDEATE is a…

  • Can the NIH replace all private sector clinical R&D?

    Can the NIH replace all private sector clinical R&D?

    A paper by Proudman et al. (2024) finds that doing so would be extremely expensive.

    4 条评论
  • Vaccine choice = more measles infection

    Vaccine choice = more measles infection

    Texas is moving to allow for more freedom of choice with respect to receipt of vaccines. The Economist reports: Texas…

    3 条评论
  • Healthcare Economist named a top 100 Economics blog

    Healthcare Economist named a top 100 Economics blog

    In Feedspot's 2025 ranking of economics blogs, Healthcare Economist was once again ranked in the top 100 (#44). I was…

    16 条评论

社区洞察

其他会员也浏览了